22Feb/100
U.S. backs Novartis vaccine, MS drug wins priority (Reuters)
Reuters - Novartis has won U.S. approval for its key Menveo meningococcal vaccine and got priority review for its oral treatment for multiple sclerosis (MS), underlining the promise of the Swiss group's pipeline.